| | Title | Author(s) | Year | View Count |
| 1 |  | Serologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance | Seto, WK; Wong, DKH; Fung, J; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, RMF | 2012 | 58 |
| 2 | | Entecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis B | Fung, J; Chan, SC; Cheung, CKY; Chok, KSH; Sharr, W; Chan, ACY; Dai, WC; Cheung, TT; Fan, ST; Lai, CL; Yuen, MF; Lo, CM | 2012 | 80 |
| 3 | | Efficacy of Chinese herbal medicine in treating liver fibrosis: a meta-analysis of 14 randomized controlled trials | Cheung, F; Feng, Y; Wang, N; Yuen, RMF; Tong, Y; Wong, VCW | 2012 | 68 |
| 4 | | Cost-effectiveness Analysis of Anti-viral Treatment in Patients with Chronic Hepatitis B Infection in Hong Kong | Lam, TP; Lam, CLK; Lai, CL; Yuen, RMF; Fong, DYT; McGhee, S; So, MK | 2012 | 70 |
| 5 | | Effect of nucleos(t)ide analogues therapy on HBsAg, intrahepatic HBV DNA and covalently closed circular DNA levels | Wong, DKH; Seto, WKW; Fung, JYY; Huang, FY; Lai, CL; Yuen, RMF | 2012 | 89 |
| 6 | | Generation of the prediction models for the development of hepatocellular carcinoma in chronic hepatitis B and external validation by independent cohorts | Kurosaki, M; Yuen, MF; Seto, WK; Kumada, T; Tanaka, K; Suzuki, Y; Hoshioka, Y; Tarnaki, N; Kato, T; Yasui, Y; Hosokawa, T; Ueda, K; Tsuchiya, K; Kuzuya, T; Nakanishi, H; Itakura, J; Takahashi, Y; Asahina, Y; Izumi, N | 2011 | 46 |
| 7 | | Entecavir monotherapy is effective in viral suppression after liver transplantation for hepatitis B. | Fung, JYY; Chan, SC; Yuen, RMF; Chok, KSH; Sharr, WW; Fan, ST; Dai, J; Seto, WK; Lo, CM | 2011 | 177 |
| 8 | | Elevation of ALT fails to predict significant histologic abnormalities in chronic hepatitis B patients. | Seto, WK; Lai, CL; Fung, JYY; Yuen, JCH; Wong, DKH; Yuen, RMF | 2011 | 130 |
| 9 |  | A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B | Lai, CL; Ahn, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NW; Kwon, YO; Sohn, JH; Lee, JY; Park, HE; Kim, JA; Han, KH; Yuen, MF | 2011 | 211 |
| 10 | | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBSAG) seroclearance | Seto, WK; Tanaka, Y; Wong, D; Lai, CL; Shinkai, N; Yuen, JCH; Tong, TSM; Fung, J; Hung, IFN; Yuen, MF | 2011 | 55 |
| 11 | | Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction | Wong, D; Lai, CL; Seto, WK; Fung, J; Huang, FY; Hung, IFN; Yuen, RMF | 2011 | 147 |
| 12 | | High prediction of hepatitis B surface antigen (HBsAg) seroclearance at 3 years of follow-up by measuring HBsAg titers | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Young, JLP; Tong, TSM; Hung, IFN; Yuen, MF | 2011 | 55 |
| 13 | | Long-term outcome of lamivudine mono-prophylaxis after liver transplantation in Hepatitis B patients | Fung, J; Chan, SC; Yuen, MF; Lai, CL; Chok, KSH; Sharr, W; Dai, WC; Fan, ST; Lo, CM | 2011 | 69 |
| 14 | | Defining normal liver stiffness values in a large population of Chinese subjects without liver disease | Fung, J; Lai, CL; Seto, WK; Wong, D; Yuen, RMF | 2011 | 52 |
| 15 | | Serum hepatitis B surface antigen (HBSAG) titers and HBV DNA levels in Hepatitis B E antigen (HBEAG)-negative chronic Hepatitis B: an interim analysis | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Young, JLP; Tong, TSM; Hung, IFN; Yuen, MF | 2011 | 51 |
| 16 | | Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B | Lai, CL; Ahh, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Yuen, MF | 2011 | 61 |
| 17 | | HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma | Wong, DKH; Huang, FY; Poon, RTP; Lai, CL; Fung, JYY; Seto, WK; Hung, IFN; Yuen, RMF | 2010 | 125 |
| 18 | | HBV DNA levels after 12 weeks of telbivudine treatment in chronic hepatitis B predicts long-term outcome | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Hung, IFN; Yuen, MF | 2010 | 186 |
| 19 | | Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks | Fung, J; Lai, CL; Wong, D; Seto, WK; Yuen, MF | 2010 | 213 |
| 20 | | Both tissue and serum dickkopf-1 (DKK-1) levels have clincopathologic and prognostic significance in hepatocellular carcinoma | Lo, RCL; Tung, EKK; Mak, CKM; Fatima, S; Zhou, H; Poon, R; Yuen, MF; Lai, CL; Li, J; Luk, JMC; Ng, IOL | 2010 | 261 |
Loading